SAN DIEGO--(BUSINESS WIRE)--At an Analyst Day event held earlier today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the recent progress of its business, its revenue growth opportunities and its portfolio of partnered assets and unpartnered development programs. Management also discussed the Captisol, LTP and SUREtechnology (owned by Selexis) formulation and delivery technologies as well as its financial outlook through 2017.“Ligand is an exciting financial story with a growing list of commercial assets, partner-driven clinical trials and core technologies,” said John Higgins, Chief Executive Officer of Ligand.
